 VANCOUVER, British Columbia--BUSINESS WIRE--Zymeworks Inc. NYSE: ZYME, a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced new and updated clinical data for the HER2targeted bispecific antibody zanidatamab, in both HER2-expressing biliary tract cancer BTC and gastroesophageal adenocarcinoma GEA. The data are being presented today at the American Society of Clinical Oncology ASCO Gastrointestinal Cancers Symposium, taking place virtua 